Key Points
Director Lawrence Erik Kurzius purchased 10,000 shares for $539,100 on September 14, 2026.
The transaction involved shares equal to 90% of the equity position held prior to the filing.
The acquisition was executed directly, bringing the Director's total ownership to 21,099 shares with no reported indirect holdings.
This open-market activity occurred as the stock's one-year return reached -19% as of the transaction date.
Lawrence Erik Kurzius, Director at The Cooper Companies, Inc. (NASDAQ:COO), acquired 10,000 shares of common stock on September 14, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $539,100 |
| Shares purchased | 10,000 |
| Post-transaction shares (directly held) | 21,099 |
| Post-transaction value | $1.14 million |
Transaction value based on SEC Form 4 weighted average purchase price ($53.91); post-transaction value based on Sept. 14, 2026 market close ($54.22).
Key questions
- What is the scale of this acquisition relative to the insider's existing stake?
The purchase of 10,000 shares represents a 90% increase in direct ownership, expanding the position from 11,099 shares to 21,099 shares. This transaction suggests a significant expansion of the Director's direct equity commitment to the medical device company. - How does the purchase price compare to the stock's recent valuation and performance?
The acquisition was completed at $53.91 per share, which was slightly below the $54.22 market close on the transaction date. As of the Sept. 15, 2026 market close, the stock was priced at $53.27, following a 19% decline in value over the 12 months ending on the trade date. - Does the insider maintain any indirect or derivative exposure to the company?
The filing indicates that all 21,099 shares are held directly by Lawrence Erik Kurzius, with no reported indirect holdings through trusts or other entities. Total beneficial ownership is comprised entirely of these direct common stock holdings, with no derivative securities disclosed in this transaction.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-15) | $53.27 |
| Market Capitalization | $10.4 billion |
| Revenue (TTM) | $4.2 billion |
| Net Income (TTM) | $570.3 million |
Company Snapshot
- The Cooper Companies develops, manufactures, and distributes a comprehensive portfolio of vision care and surgical products through two primary business units: CooperVision, which specializes in contact lenses, including spherical, toric, multifocal, and myopia management solutions, and CooperSurgical, which provides surgical instruments and supplies for ophthalmic and women's health procedures.
- The company generates revenue through the sale of contact lens products, surgical instruments, and related healthcare supplies to eye care professionals, surgical centers, and healthcare providers globally, leveraging a diversified product portfolio across multiple therapeutic categories and geographic markets.
- The Cooper Companies serves eye care practitioners, ophthalmologists, surgical centers, and healthcare institutions worldwide, with particular focus on patients requiring vision correction solutions and healthcare providers performing ophthalmic and women's health surgical procedures.
The Cooper Companies is a global medical device manufacturer with approximately 15,000 employees and a market capitalization of $10.4 billion, generating $4.2 billion in trailing twelve-month (TTM) revenue. The company maintains a competitive position in the vision care and surgical markets through its dual-business-unit structure, offering both consumer-facing contact lens products and professional-grade surgical instruments that address substantial global demand for vision correction and surgical solutions.
What this transaction means for investors
Kurzius is an independent director of the company. He also serves as CEO of McCormick & Co (NYSE:MCK), so he knows what the market is looking for in a publicly traded company. It's bullish that he is buying shares.
CooperCompanies is one of the largest eyecare companies in the U.S, and one of the four dominant businesses in contact lenses. Cooper was considering spinning off or selling its surgical unit, but opted to keep it in-house. That's a sign that they believe there is more value to owning the business ahead. For the current fourth quarter of its fiscal year, the company expects consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%. That's not great, but management believes it sets the stage for a better 2027.
The lack of a spin-off disappointed a lot of investors and is the reason for the stock's slump of late. Kurzius' buying here has the hallmarks of a buy-low move. After all, there are many reasons an insider may sell a company's shares. One reason could be the need to raise cash to fund a large personal expense. Another reason could be for a reasonable portfolio diversification unrelated to their outlook for the company. A third reason could be what investors fear most: a bearish outlook on the company's future.
However, there is only one reason an insider buys stock: they believe the share price is going up.
By that investor's rule of thumb, Kurzius's purchase of Cooper Companies's shares is inherently bullish.
On top of that, studies show that, more often than not, an insider purchase predicts a higher share price 30 days later.
Insider buying like this is a signal to investors to take a closer look at a stock like COO and decide if it fits with their long-term investment plan. Evidently, it fits with Kurzius'.
Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool recommends McKesson. The Motley Fool has a disclosure policy.